Tucatinib 50 mg, 150 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 50 mg, 150 mg

Reference Brands: Tukysa (USA, EU/UK), Tukavo (India)

Category: Oncology Cancer Care

Tucatinib tablets (50 mg, 150 mg) are a HER2-selective tyrosine kinase inhibitor used with trastuzumab and capecitabine for HER2-positive metastatic breast cancer, including brain metastases, and for HER2-positive colorectal cancer. The originator product is Tukysa (Pfizer); a version is also sold in India. Patent status differs by country, so we confirm what can lawfully be supplied to your destination before quoting.

Product Description:

Tucatinib is an oral anticancer medication used in the treatment of HER2-positive cancers, particularly advanced or metastatic breast cancer. It is a small-molecule inhibitor that selectively targets the human epidermal growth factor receptor 2 (HER2), a protein that promotes the growth of certain cancer cells. By blocking HER2 signaling pathways, tucatinib helps slow down tumor growth and reduce the spread of cancer. This targeted mechanism allows it to work effectively while minimizing effects on other receptors compared to some older therapies.

Tucatinib is commonly used in combination with other anticancer medicines such as trastuzumab and capecitabine to improve treatment outcomes in patients who have previously received other HER2-directed therapies. One of the important advantages of tucatinib is its ability to provide benefits for patients whose cancer has spread to the brain, a condition that can be difficult to treat with many standard therapies. The medicine is administered orally in tablet form, making it convenient for ongoing treatment.

Overall, tucatinib represents an important advancement in targeted oncology therapy, offering an additional option for managing HER2-positive cancers and improving disease control in patients with advanced stages of the disease.